넥타테라퓨틱스 (NKTR)

May 02, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 02, 2025

May 01, 2025

Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets - Longview News-Journal

May 01, 2025

May 01, 2025

Nektar to Announce Financial Results for the First Quarter on Th - GuruFocus

May 01, 2025

May 01, 2025

Upcoming Nektar Q1 2025 Earnings Call: CEO Howard Robin to Present Financial Results May 8 - Stock Titan

May 01, 2025

May 01, 2025

Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance

May 01, 2025

Apr 16, 2025

Treg Cell-Based Therapies Pipeline: 51+ Innovators Shaping the Future of Immunotherapy | DelveInsight - openPR.com

Apr 16, 2025

Apr 16, 2025

Nektar upgraded at Jefferies ahead of mid-stage readout for eczema drug - MSN

Apr 16, 2025

Apr 13, 2025

Nektar Therapeutics (NKTR) Shares Surge on Jefferies Upgrade - GuruFocus

Apr 13, 2025

Apr 12, 2025

Jefferies Upgrades Nektar Therapeutics (BMV:NKTR) - Nasdaq

Apr 12, 2025

Apr 12, 2025

Nektar Therapeutics (NKTR) Gains After Jefferies Upgrade - GuruFocus

Apr 12, 2025

Apr 11, 2025

Jefferies Upgrades Nektar Therapeutics (NKTR) - MSN

Apr 11, 2025

Apr 11, 2025

Sector Update: Health Care - TradingView

Apr 11, 2025

Apr 11, 2025

Jefferies Upgrades Nektar Therapeutics (LSE:0UNL) - Nasdaq

Apr 11, 2025

Apr 11, 2025

Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00 - Yahoo Finance

Apr 11, 2025

Apr 11, 2025

Nektar Therapeutics Shares Rise After Upgrade From Jefferies - marketscreener.com

Apr 11, 2025

Apr 11, 2025

Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report? - Yahoo Finance

Apr 11, 2025

Apr 11, 2025

Nektar Therapeutics stock upgraded at Jefferies (NKTR:NASDAQ) - Seeking Alpha

Apr 11, 2025

Apr 11, 2025

Assessing Nektar Therapeutics: Insights From 5 Financial Analysts - Benzinga

Apr 11, 2025

Apr 11, 2025

Jefferies Upgrades Nektar Therapeutics to Buy From Hold, Adjusts Price Target to $2 From $1 - marketscreener.com

Apr 11, 2025

Apr 11, 2025

Jefferies raises Nektar stock to buy, doubles price target By Investing.com - Investing.com India

Apr 11, 2025

Apr 11, 2025

Jefferies Upgrades Nektar Therapeutics (NKTR) to Buy - StreetInsider

Apr 11, 2025

Apr 10, 2025

IL-2 ADding contenders in eczema strategy - BioWorld MedTech

Apr 10, 2025

Apr 09, 2025

Nektar Therapeutics stock hits 52-week low at $0.44 By Investing.com - Investing.com Canada

Apr 09, 2025

Apr 09, 2025

Nektar Therapeutics stock hits 52-week low at $0.44 - Investing.com

Apr 09, 2025

Apr 07, 2025

Advanced Urothelial Carcinoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - Barchart.com

Apr 07, 2025

Apr 04, 2025

Little Excitement Around Nektar Therapeutics' (NASDAQ:NKTR) Revenues As Shares Take 29% Pounding - simplywall.st

Apr 04, 2025

Mar 31, 2025

Q1 Dermatology Drug & Device Report: FDA Approvals & Pipeline Updates - Dermatology Times

Mar 31, 2025

Mar 29, 2025

Nektar Therapeutics announces $75 million equity distribution - Investing.com Australia

Mar 29, 2025

Mar 29, 2025

Nektar Therapeutics announces $75 million equity distribution By Investing.com - Investing.com India

Mar 29, 2025

Mar 28, 2025

Nektar TherapeuticsEnters Equity Distribution Agreement Up To $75 MillionSEC Filing - Marketscreener.com

Mar 28, 2025

Mar 28, 2025

Nektar Therapeutics (NKTR) Files $300M Mixed Securities Shelf Of - GuruFocus

Mar 28, 2025

Mar 28, 2025

Nektar Therapeutics Files For Mixed Shelf Offering Of Up To $300 MillionSEC Filing - MarketScreener

Mar 28, 2025

Mar 28, 2025

Nektar Therapeutics (NKTR) Files $300M Mixed Shelf - StreetInsider

Mar 28, 2025

Mar 28, 2025

IL-2s gain ground as US market heads for $4 billion by 2034 - The Pharma Letter

Mar 28, 2025

Mar 27, 2025

The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Disorders, and Oncology | DelveInsight - Yahoo Finance

Mar 27, 2025

Mar 27, 2025

Nektar at H.C. Wainwright Conference: Strategic Updates on Respegg Trials - Investing.com

Mar 27, 2025

Mar 24, 2025

Petrelintide up front shatters biotech deal record - BioCentury

Mar 24, 2025

Mar 22, 2025

Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil - Insider Monkey

Mar 22, 2025

Mar 20, 2025

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - Lelezard

Mar 20, 2025

Mar 20, 2025

Nektar Therapeutics to Present Autoimmune Disease Updates at HC Wainwright Conference | NKTR Stock News - Stock Titan

Mar 20, 2025

Mar 17, 2025

Oppenheimer Upgrades Nektar Therapeutics (BMV:NKTR) - Nasdaq

Mar 17, 2025

Mar 14, 2025

Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up - MSN

Mar 14, 2025

Mar 14, 2025

Nektar upgraded at Oppenheimer on upcoming mid-stage trial readout - MSN

Mar 14, 2025

Mar 14, 2025

Nektar Therapeutics (NASDAQ:NKTR) Q4 2024 Earnings Call Transcript - MSN

Mar 14, 2025

Mar 14, 2025

Oppenheimer Upgrades Nektar Therapeutics (NKTR) - Nasdaq

Mar 14, 2025

Mar 14, 2025

NEKTAR THERAPEUTICS SEC 10-K Report - TradingView

Mar 14, 2025

Mar 14, 2025

Nektar Therapeutics Shares Rise After Upgrade From Oppenheimer -March 14, 2025 at 02:54 pm EDT - Marketscreener.com

Mar 14, 2025

Mar 14, 2025

Oppenheimer Upgrades Nektar Therapeutics (LSE:0UNL) - Nasdaq

Mar 14, 2025

Mar 14, 2025

Nektar stock upgraded at Oppenheimer (NKTR:NASDAQ) - Seeking Alpha

Mar 14, 2025